Findings

What do systematic reviews say?

821 questions · 842 findings · 96 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 275 · 32.7%GRADE not reported 88 · 10.5%Very low 197 · 23.4%Low 187 · 22.2%Moderate 86 · 10.2%High 9 · 1.1%

Rutosides vs an alternative venoactive remedy (hidrosmina)

Adverse effects · patients with PTS

The review found no eligible studies for this question.

1 finding from 1 review

Rutosides for treatment of post‐thrombotic syndrome 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Rutosides vs an alternative venoactive remedy (hidrosmina)

Occurrence of leg ulceration · patients with PTS

The review found no eligible studies for this question.

1 finding from 1 review

Rutosides for treatment of post‐thrombotic syndrome 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Major bleeding · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in major bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.77 [0.39, 1.53]
4 studies · 1055 participants
Low

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Minor bleeding · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in minor bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.83 [0.57, 1.23]
4 studies · 1055 participants
Low

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Thrombocytopenia · patients with active cancer with venous thromboembolism

The review found no eligible studies for this question.

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Health related quality of life · patients with active cancer with venous thromboembolism

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 8485 participants
Moderate

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

All‐cause mortality · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.94 [0.72, 1.23]
4 studies · 1060 participants
Low

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Recurrent venous thromboembolism · patients with active cancer with venous thromboembolism

Direct oral anticoagulant secondary prophylaxis showed no clear difference in recurrent venous thromboembolism compared with vitamin K antagonist secondary prophylaxis (low certainty).

1 finding from 1 review

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
RR 0.63 [0.34, 1.15]
4 studies · 1050 participants
Low

Cannabis cigarettes (115 mg THC) vs placebo cigarettes

Clinical remission · Patients with active Crohn's disease

It is very uncertain whether cannabis cigarettes (115 mg THC) changes proportion of patients achieving clinical remission compared with placebo cigarettes (very low certainty).

1 finding from 1 review

Cannabis for the treatment of Crohn's disease 2018 · Cochrane Headline outcomes only
RR 4.55 [0.63, 32.56]
1 study · 21 participants
Very low

Cannabis oil (5% cannabidiol sublingual oil) vs placebo oil

CRP (mg/dL) at end of study · Patients with active Crohn's disease

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis for the treatment of Crohn's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cannabis oil (5% cannabidiol sublingual oil) vs placebo oil

Quality of life · Patients with active Crohn's disease

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis for the treatment of Crohn's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cannabis oil (5% cannabidiol sublingual oil) vs placebo oil

Adverse events · Patients with active Crohn's disease

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis for the treatment of Crohn's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cannabis oil (5% cannabidiol sublingual oil) vs placebo oil

Serious adverse events · Patients with active Crohn's disease

It is very uncertain whether cannabis oil (5% cannabidiol sublingual oil) changes serious adverse events compared with placebo oil (very low certainty).

1 finding from 1 review

Cannabis for the treatment of Crohn's disease 2018 · Cochrane Headline outcomes only
RR 0.9 [0.07, 12.38]
1 study · 19 participants
Very low

Cannabis oil (5% cannabidiol sublingual oil) vs placebo oil

Withdrawals due to adverse events · Patients with active Crohn's disease

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis for the treatment of Crohn's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cannabis oil (15% cannabidiol and 4% THC) vs placebo oil

Clinical remission · Patients with active Crohn's disease

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis for the treatment of Crohn's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cannabis oil (15% cannabidiol and 4% THC) vs placebo oil

Proportion of patients achieving clinical response · Patients with active Crohn's disease

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis for the treatment of Crohn's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cannabis oil (15% cannabidiol and 4% THC) vs placebo oil

CRP (mg/dL) at end of study · Patients with active Crohn's disease

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis for the treatment of Crohn's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cannabis oil (15% cannabidiol and 4% THC) vs placebo oil

Quality of life Short‐Form 36 health survey (SF‐36) · Patients with active Crohn's disease

1 finding from 1 review

Cannabis for the treatment of Crohn's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 39 participants
Low

Cannabis oil (15% cannabidiol and 4% THC) vs placebo oil

Adverse events · Patients with active Crohn's disease

The review found no eligible studies for this question.

1 finding from 1 review

Cannabis for the treatment of Crohn's disease 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cannabis cigarettes (115 mg THC) vs placebo cigarettes

Proportion of patients achieving clinical response · Patients with active Crohn's disease

It is very uncertain whether cannabis cigarettes (115 mg THC) changes proportion of patients achieving clinical response compared with placebo cigarettes (very low certainty).

1 finding from 1 review

Cannabis for the treatment of Crohn's disease 2018 · Cochrane Headline outcomes only
RR 2.27 [1.04, 4.97]
1 study · 21 participants
Very low